MCC 565
Latest Information Update: 17 Mar 2003
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Bisphosphonates; Osteoporosis therapies
- Mechanism of Action Estradiol 17 beta dehydrogenase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 17 Mar 2003 No development reported - Preclinical for Osteoporosis in Japan (unspecified route)
- 05 Apr 2001 Preclinical development for Osteoporosis in Japan (Unknown route)